This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Sandbox 127

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 48: Line 48:
efficiently react with the serine active site residue and therefore inhibit the activity of
efficiently react with the serine active site residue and therefore inhibit the activity of
PBP2a.
PBP2a.
 +
 +
 +
 +
 +
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
 +
neither bound nor inhibited by β-lactams. Recently, two cephalosporins –
 +
<scene name='37/372724/Ceftobiprole/1'>ceftobiprole</scene> and
 +
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
 +
inhibit PBP2a because additional chemical groups at the
 +
<scene name='37/372724/Ceftobiprole/7'>R2</scene>
 +
position of the cephalosporin backbone are able to interact with additional amino acid
 +
residues in PBP2a; specifically
 +
<scene name='37/372724/Tyr446_and_met641_label/2'>Tyr446 and Met641</scene>.
 +
As a result of ceftobiprole <scene name='37/372724/R2_interaction/4⅝'>tighter binding</scene> to PBP2a as highlighted in green , <scene name='37/372724/Ceftobiprole_in_cpk/1'>the medicine</scene>, shown as colors of the atom types ([[CPK]]), is able to more efficiently react with the serine active site residue and therefore inhibit the activity of PBP2a.
 +
 +
 +
 +
<scene name='37/372724/R2_interaction/6'>tighter binding</scene>

Revision as of 16:59, 15 August 2013

Drag the structure with the mouse to rotate
Personal tools